Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic Genotype 2 or 3 HCV-infection
Naive to all HCV antiviral treatment(s)
You may not be if
Positive test at Screening for HBsAg, anti-hepatitis B core immunoglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab
History of any other clinically significant chronic liver disease
A history consistent with decompensated liver disease
History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, seizure disorder or anticonvulsant use, poorly controlled diabetes, cancer, or a history of malignancy, that makes the subject unsuitable for the study.
Participation in a clinical study within 3 months prior to first dose
Clareo Health | Phase 3 Study of Sofosbuvir and Ribavirin
